← Traws Pharma, Inc. (TRAW) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Traws Pharma, Inc. (TRAW)
Pharmaceutical Preparations · market cap $7M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
7
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Traws Pharma (TRAW) is a micro-cap pharmaceutical company with a $10M market cap, 6 employees, and ~$3.1M cash representing roughly 3.6 months of runway. The company runs a broad pipeline spanning oncology (gemcitabine Phase 3 in metastatic pancreatic adenocarcinoma, rigosertib in MDS and HNSCC, narazaciclib in endometrial cancer) and antivirals (ratutrelvir for COVID-19, TRX-100 for influenza), though several assets appear to be repurposed or partnered compounds rather than proprietary novel therapies.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · TRX-100imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Oral rigosertib | Phase 2 | Myelodysplastic Syndromes |
| Ratutrelvir (83-0060) non-randomised | Phase 2 | COVID - 19 |
| rigosertib | Phase 2 | Head and Neck Squamous Cell Carcinoma |
| Narazaciclib | Phase 2 | Endometrioid Endometrial Cancer |
| rigosertib sodium | Phase 3 | Myelodysplastic Syndromes |
| ON 01910.Na | Phase 3 | Myelodysplastic Syndrome |
| TRX-100 | Phase 2 | Influenza |
Price & technical context
3-month
-26.9%
6-month
-65.2%
12-month
-68.7%
52-wk range
$0.44–$3.13
vs 50-day MA
+5.3%
vs 200-day MA
-54.8%
Realized vol
133.9%
Max drawdown
-96.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TRAW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.